Dr. David S. Wilkes, Dean of the UVA School of Medicine, will join us for a conversation on his experience commercializing research from his lab to form ImmuneWorks.
Dean Wilkes has co-authored more than 100 research papers, holds six U.S. patents and co-founded ImmuneWorks Inc., which researched and developed treatments for immune-mediated lung diseases that include lung transplant rejection and idiopathic pulmonary fibrosis.
Further Background:
Dr. David S. Wilkes joined School of Medicine as dean in September 2015. A board-certified specialist in pulmonary disease and critical care medicine, prior to joining the University of Virginia he served as executive associate dean for research affairs at the Indiana University School of Medicine. Dr. Wilkes previously served as the Indiana University’s assistant vice president for research and as director of the Strategic Research Initiative for the Indiana University School of Medicine and Indiana University Health. He was also director of the Indiana University School of Medicine’s Physician Scientist Initiative.
He has served as a permanent member of study sections at the National Institutes of Health (NIH), as well as a member of the National Advisory Council for the National Institutes of Allergy and Infectious Diseases. Dr. Wilkes is a current member of the Board of Scientific Counselors for the National Heart, Lung and Blood Institute at NIH. Discoveries from Dr. Wilkes’ lab were the basis for his founding ImmuneWorks, a biotech company developing novel therapeutics for immune-mediated lung diseases. He is also the national director of the Harold Amos Medical Faculty Program for the Robert Wood Johnson Foundation, one of the nation’s leading programs in training physician scientists.